ARCHIVES

Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 37 No. 6 | June 27, 2014

Download PDF Visit The Full Archive

Related Articles

Docetaxel As Adjuvant Therapy Shows Benefit Over Standard

June 28, 2002

Byrd Seeks Federal Tar-Nicotine Limit

October 22, 1976

Panel to Hear Innovation Reports

August 26, 1988

Advisors approve NCI’s revised plan for $104-million proteomics research program.

July 8, 2005

New Jersey Center To Have Two Alliances: One With CINJ—and One With MD Anderson

June 21, 2013

In Brief: GAO Probe Of Cancer Control Program Nears End; Renewal Bill Mark Up Not Before Oct. 22

October 12, 1979